Hearscape
← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry+publication

Sun Yat-sen NAD+ Coenzyme I SSNHL Study

Also known as: Small Sample, Unicentric, Randomized, Controlled Clinical Study of Coenzyme I for Injection in the Treatment of Sudden Sensorineural Hearing Loss, NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss, NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial, Coenzyme I for Injection plus conventional treatment, NAD+ plus standard treatment, Coenzyme I, NAD+, NCT05849519

Institution-led study

Primary source
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 1
Status
Completed
Target Gene
—
Route / Mode
Injection with standard sudden-hearing-loss treatment
Confidence
90%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
China
Population
adult, older-adult, sudden, sensorineural, unilateral, tinnitus
Trial IDs
1
Mechanism

Academic randomized controlled study evaluating injected NAD+ / Coenzyme I added to standard treatment for adult unilateral sudden sensorineural hearing loss. The comparator is standard/conventional treatment, so the control arm should not appear as a separate HearScape therapeutic program.

Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing Loss
Notes

Promoted as a verified publication-backed academic NAD+/Coenzyme I study in sudden sensorineural hearing loss. The conventional-treatment arm is a comparator and should not appear as a separate HearScape program.

Evidence & Sources
5 structured sources
clinicaltrials
Supports: canonicalName, aliases, company, programType, modality, indications, stage, route...
IDs: NCT05849519
Open
publication
Supports: canonicalName, aliases, mechanism, status, populationTags, notes, keyEvents
IDs: PMID:41035311, PMCID:PMC12913733, NCT05849519
Open
publication
Supports: canonicalName, aliases, mechanism, status, populationTags, notes, keyEvents
IDs: PMCID:PMC12913733, NCT05849519
Open
publication
Supports: canonicalName, mechanism, status, notes, keyEvents
IDs: DOI:10.1002/lary.70173, NCT05849519
Open
registry mirror
Supports: canonicalName, aliases, stage, route, notes
IDs: NCT05849519
Open
Key Events
2022-02-16
Registry lists study start date for the Sun Yat-sen Coenzyme I/NAD+ SSNHL study
2023-05-09
ClinicalTrials.gov first posted the Coenzyme I for Injection SSNHL study
2025-10-01
Laryngoscope published the randomized controlled trial of NAD+ for SSNHL hearing recovery
Clinical Trials (1)
NCT05849519
Data Checks
institution-led-studymerged-generated-intervention-armsstudy-level-not-standalone-productpublished-randomized-controlled-trialnot-confirmed-current-product
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2